Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5599919 A
Publication typeGrant
Application numberUS 08/353,700
Publication dateFeb 4, 1997
Filing dateDec 9, 1994
Priority dateDec 9, 1994
Fee statusPaid
Also published asCA2208052A1, WO1996017867A1
Publication number08353700, 353700, US 5599919 A, US 5599919A, US-A-5599919, US5599919 A, US5599919A
InventorsTimothy J. Yen, Jerome B. Rattner
Original AssigneeFox Chase Cancer Center, Uti, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Nucleic acid encoding a transiently-expressed kinetochore protein, and methods of use
US 5599919 A
Abstract
An isolated nucleic acid is provided which encodes a transiently-expressed kinetochore protein, CENP-F. Also provided are the purified polypeptide encoded by the nucleic acid sequence, and antibodies immunologically specific for the polypeptide. These biological molecules are useful as markers of cellular proliferation, particularly for the identification of cells in the G2 and M phases of the cell cycle. Methods are provided for using the nucleic acid, protein and antibodies for assessing cellular proliferation in biological fluids and tissue samples, and for detecting the presence of autoantibodies to the protein.
Images(1)
Previous page
Next page
Claims(6)
What is claimed is:
1. An isolated, purified nucleic acid molecule that encodes a human kinetochore protein transiently expressed during G2 and M phases of a cell cycle, said protein having a molecular weight between about 340 kD and 420 kD, said protein having a general structure comprising two extended coil domains flanking a non-coil core domain, at least one nuclear localization consensus signal at the amino terminus, a conserved P-loop nucleotide binding site at the carboxyl terminus, and lacking the conserved helix-loop-helix domain characteristic of the SMC family of chromosome condensation proteins.
2. The nucleic acid molecule of claim 1, wherein said sequence encodes a polypeptide approximately 3,248 amino acids in length.
3. The nucleic acid of claim 1, which is RNA.
4. The nucleic acid of claim 1, which is DNA.
5. An isolated and purified nucleic acid molecule which encodes a polypeptide having the amino acid sequence of SEQ ID NO: 1.
6. The nucleic acid of claim 5, which has the sequence of SEQ ID NO: 2.
Description

Pursuant to 35 U.S.C. §202(c), it is hereby acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with funds from the National Institutes of Health.

FIELD OF THE INVENTION

This invention relates to detection of cellular proliferation for diagnosis and prognosis of neoplastic disease. More particularly, this invention provides a novel nucleic acid molecule, protein and antibodies useful for detecting cellular proliferation.

BACKGROUND OF THE INVENTION

The centromere is a multi-functional chromosomal domain that plays a major role in cell proliferation by mediating both chromosome movement and sister chromatid association during cell division. The kinetochore is a highly complex macromolecular structure associated with centromeric heterochromatin. The kinetochore is responsible for establishing and maintaining connections with microtubules of the mitotic spindle.

The identification and molecular cloning of many proteins of the centromere-kinetochore complex, using autoimmune sera and biochemical fractionation, has provided the necessary reagents to investigate the biochemical structure and function of the complex. The collection of proteins thus identified can be separated into two classes, based on their distribution during various times of the cell cycle. One class, the DNA- or chromatin-binding proteins, CENP-A, B, and C, are constitutive centromere proteins, inasmuch as they can be detected throughout interphase, at discrete loci within the nucleus (presumably centromere chromatin), or localized within the centromere-kinetochore complex during mitosis. The other class, comprising well-characterized proteins such as INCENP and CENP-E belong to the facultative family of centromere-kinetochore proteins, because of the transient nature of their association with the kinetochore complex. In the case of the kinesin-like CENP-E protein, it accumulates to high levels in the cytoplasm of interphase cells and assembles onto kinetochores of prometaphase chromosomes after nuclear envelope breakdown.

Measures of cell proliferation, including direct counts of mitotic figures, thymidine labelling, bromodeoxyuridine incorporation, determination of nucleolar morphology and flow cytometry, have been found to be prognostic indicators for a variety of tumor types. In addition, several proliferation-associated nuclear antigens have been identified which have allowed the direct detection and quantitiation of cycling cells by indirect immunofluorescence. One of these, Proliferating Cell Nuclear Antigen (PCNA), is a 36 kDa protein first identified by autoantibodies associated with autoimmune disease (Miyachi et al., J. Immunol. 121: 2228-2234, 1978). This protein is an auxiliary protein of DNA polymerase delta, a nuclear protein that is present throughout the cell cycle but is maximally expressed in the Gl-S phase (Matthews et al., Nature 303: 374-376, 1984). Several reports indicate that PCNA expression is deregulated in tumor cells, making the use of this antigen as a marker of tumor cell proliferation problematic (Hall et al., J. Pathol. 161: 285-294, 1990). A second cell cycle related antigen recognized by the monoclonal antibody Ki-67 has also been used to identify proliferating cells (Gerdes et al., Int. J. Cancer 31: 13-20, 1983). Like Ki-67, K1-K1 is detected from the G1 boundary of the cell cycle through M-phase. However, in contrast to Ki-67, Ki-S1 can be detected in paraffin embedded tissues. One major limitation of all three proliferating cell antigens described above is that they are detected throughout a major portion of the cell cycle, making them of limited use when specific cell cycle information is desired.

We recently identified a novel .ca 400 kDa cell cycle-dependent kinetochore associated protein in human cells, designated CENP-F, using human autoimmune serum (Rattner et al., Cell Motility and the Cytoskeleton 26: 214-226, 1993). Immunofluorescence staining of CENP-F revealed that it was homogeneously distributed throughout the nucleus of HeLa cells in the G2 stage of the cell cycle, and then localized to the centromere region of the chromosomes at prophase after G2. Similar to CENP-E, CENP-F appeared to localize to the outer layer of the kinetochore and was subsequently found at the spindle midzone and within the intercellular bridge during the later part of mitosis. CENP-F was not detected during the G1 phase of the cell cycle, and was presumed discarded or degraded after cytokinesis.

Amongst the small number of facultative centromere-kinetochore proteins that have identified thus far, CENP-F appears to be the earliest member to interact with the centromere-kinetochore complex. For example, the appearance of CENP-F at the centromere-kinetochore region at prophase precedes the appearance of CENP-E. Thus, antibodies immunologically specific for CENP-F could enable the specific detection of G2 and M-phase cells in cultured cells or in tissues, rendering CENP-F a useful addition to the cell cycle specific markers used to study cell proliferation in tumor samples. However, to date, little information is available regarding the molecular characterization of CENP-F; the isolated purified CENP-F protein has heretofore been unavailable, and likewise, nucleic acids encoding the protein have not been produced.

It is an object of the present invention to provide an isolated, purified, nucleic acid molecule that encodes the entire CENP-F polypeptide. It is further an object of the invention to provide an isolated, purified form of the CENP-F protein, and to provide antibodies immunologically cross-reactive with the protein. The nucleic acid, protein and antibodies thereto may be used to advantage in diagnostic and prognostic assays for the detection and measurement of cellular proliferation in cultured cells and in tissues. The use of CENP-F as a cell cycle-specific marker advantageously allows the specific detection of G2 and M-phase cells, which other known cell cycle-specific markers are unable to specifically target. Additionally, the CENP-F protein itself provides the additional benefit of use for detecting autoimmune antibodies to the protein, which may provide an early diagnosis for the onset of various malignant diseases.

SUMMARY OF THE INVENTION

According to one aspect of the present invention, an isolated, purified nucleic acid molecule is provided, which includes a sequence encoding a kinetochore protein, referred herein as CENP-F. The protein is transiently expressed substantially during the G2 and M phases of a cell cycle. To explain the term "substantially during," the protein is detected by immunofluorescence microscopy only during the G2 and M phases of the cell cycle. By Western blot analysis, however, low levels of the protein may be detected at other phases of the cell cycle, but a much high-fold level is detected at the G2 and M phases. The CENP-F protein encoded by the nucleic acid has a molecular weight of between about 340 kDa and 420 kDa, and possesses a general structure comprising two extended coil domains flanking a non-coil core domain.

In a preferred embodiment of the invention, the nucleic acid sequence is of human origin, encoding a polypeptide of approximately 372 kDa in molecular weight and approximately 3248 amino acids in length.

According to another aspect of the present invention, a isolated and purified kinetochore protein, CENP-F, is provided, which is transiently expressed substantially during G2 and M phases of a cell cycle. The protein is preferably of human origin, having the structural characteristics as described above.

According to another aspect of the present invention, antibodies are provided that are immunologically specific for part or all of the isolated protein of the invention. The antibodies may be polyclonal or monoclonal.

According to another aspect of the invention, methods are provided for using the nucleic acid, protein and antibodies of the invention for assessing cellular proliferation in biological fluids and tissues. A method is provided for detecting the presence of autoantibodies to CENP-F in a biological fluid. The method comprises detectably labelling an isolated, purified protein of the invention; preparing a test sample of the biological fluid suspected of containing the autoantibody; contacting the test sample with the detectably labelled protein such that the autoantibody, if present, forms a detectable complex with the labelled protein; and thereafter detecting the complex. Methods are also provided for detecting the presence of CENP-F protein, or nucleic acids encoding the protein, in a biological fluid, cell or tissue. To detect the protein, the method comprises preparing an antibody immunologically specific for the protein; detectably labelling the antibody, preparing a test sample of the biological fluid, cell or tissue suspected of containing the protein; contacting the test sample with the detectably labelled antibody such that the protein, if present, forms a detectable complex with the antibody; and detecting the complex. For detecting a nucleic acid, the method involves preparing a nucleotide probe that specifically hybridizes with the nucleic acid. The nucleotide probe is detectably labelled, a test sample of the biological fluid, cell or tissue suspected of containing the nucleic acid is prepared, and the test sample is contacted with the nucleotide probe such that the nucleic acid, if present, forms a detectable complex with the nucleotide probe. The detectable complex is thereafter detected.

In a preferred embodiment, the foregoing methods may be adapted to measure the quantity of autoantibodies, nucleic acid, or CENP-F protein in a test sample by detectably labelling the appropriate biological reagent with a quantifiable label. Such a label may be radioactive, fluorescent, luminescent, or absorptive of electromagnetic radiation, and the detectable complex may be quantified by a variety of methods known in the art.

The nucleic acids, protein and antibodies of the invention advantageously enable detection and measurement of cellular proliferation in biological fluids, cultured cells and tissues, and are particularly useful for the specific detection of G2 and M-phase cells. Moreover, the isolated CENP-F protein of the invention is useful for detecting autoantibodies to the protein, which may provide an early indication of malignant disease.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram of the human CENP-F-encoding cDNA clone having Sequence I.D. Number 2. The upper of portion of the Figure depicts the full-length cDNA; stippled and hatched regions of the full-length cDNA denote fragments used for expression of protein; "RI" denotes EcoRI restriction sites. The lower portion of the Figure depicts cDNA fragments (D1-D10, 7-1)isolated by antibody screening of expression libraries or synthesized in 5' extension reactions (RACE).

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have produced a nucleic acid molecule having a sequence that encodes human CENP-F, a novel kinetochore protein recently identified by immunological reaction with an autoimmune serum (Rattner, et al., 1993, supra). Analysis of the nucleotide sequence of a 10.1 kb human cDNA encoding CENP-F revealed that it encodes a 372 kDa protein comprising epitopes that cross-react with the previously-described autoimmune serum. The protein encoded by the cDNA is referred to herein as Sequence I.D. No. 1. The cDNA is referred to as Sequence I.D. No. 2. Prior to the invention disclosed herein, little was known of the CENP-F protein aside from its approximate molecular weight (.ca 400 kDa) and its cellular distribution at different cell cycle times. The cloning and analysis of a cDNA encoding human CENP-F is described in detail in Example 1.

In accordance with the present invention, analysis of the deduced amino acid sequence of the aforementioned cDNA reveals that the 372 kDa protein encoded by the cDNA does not appear to be homologous to any known proteins. However, the polypeptide exhibits remarkable structural similarity to an emerging SMC family of chromatin compaction proteins (see C. L. Peterson, Cell 79: 389-392, 1994). Similar to other SMC proteins, CENP-F is predicted to possess two large coil domains that flank a central core. However, the notable absence of a conserved helix-loop-helix motif and the location of a conserved P-loop NTP binding site at the carboxyl, rather than the amino, terminus suggests that CENP-F is a distant relative of the SMC family. A more detailed structural description of CENP-F is set forth in Example 1.

Immunofluorescence and expression studies reveal that CENP-F localization and expression are cell cycle dependent. Low levels of CENP-F are detected in G1 but dramatically increase as cells progress toward mitosis, and decrease when cells complete mitosis. Since the synthetic rate of CENP-F increases only moderately at late stages of the cell cycle, the rise in steady-state levels is likely due to the stability of the protein. As described in Example 1, pulse-chase experiments revealed that the half-life of CENP-F is approximately 4.5 hours during late G1 and S phase, but is shortened to less than two hours when cells progress through mitosis. The accelerated decay of CENP-F is coupled to mitotic progression, since the protein is stabilized when cells are blocked from completing mitosis. Amongst the chromosome passenger family, CENP-F appears to bind to kinetochores the earliest. CENP-F appears to be one of the proteins to initiate the formation and maturation of the kinetochore trilaminar plates.

Because of its specific appearance and accumulation in the G2 phase of the cell cycle, CENP-F should prove to be particularly useful as a marker of cellular proliferation. The CENP-F-encoding nucleic acids, recombinant proteins and antibodies thereto described herein are advantageously utilized for the detection and quantitation of CENP-F in tissues and cultured cells, and particularly to identify cells in the G2 phase. Additionally, purified recombinant CENP-F, as described herein, may be labelled and used as a general screen to detect circulating autoantibodies in human patients. As explained in greater detail in Example 2, it appears that the presence of circulating autoantibodies to CENP-F (as well as other cell cycle-dependent proteins) may provide an early indication of malignant disease.

The CENP-F-encoding cDNA having Sequence I.D. No. 2 was constructed by repeated antibody probing of a human breast carcinoma cDNA expression library. Allelic variants and natural mutants of Sequence I.D. No. 2 are likely to exist within the human genome and within the genomes of other species. Because such variants are expected to possess certain differences in nucleotide and amino acid sequence, this invention provides an isolated nucleic acid molecule and an isolated CENP-F protein having at least about 50-60% sequence homology in the coding region with the nucleotide sequence set forth as Sequence I.D. No. 2 (and, preferably, specifically comprising the coding region of sequence I.D. No. 2), and the amino acid sequence of Sequence I.D. No. 1. Because of the natural sequence variation likely to exist among CENP-F proteins and nucleic acids encoding them, one skilled in the art would expect to find up to about 40-50% sequence variation, while still maintaining the unique properties of the CENP-F protein of the present invention. Such an expectation is due in part to the degeneracy of the genetic code, as well as to the known evolutionary success of conservative amino acid sequence variations, which do not appreciably alter the nature of the protein. Accordingly, such variants are considered substantially the same as one another and are included within the scope of the present invention. For purposes of this invention, the term "substantially the same" refers to nucleic acid or amino acid sequences having sequence variation that do not materially affect the nature of the protein (i.e. the structure and/or biological activity of the protein). With particular reference to nucleic acid sequences, the term "substantially the same" is intended to refer to the coding region and to conserved sequences governing expression, and refers primarily to degenerate codons encoding the same amino acid, or alternate codons encoding conservative substitute amino acids in the encoded polypeptide. With reference to amino acid sequences, the term "substantially the same" refers generally to conservative substitutions and/or variations in regions of the polypeptide not involved in determination of structure or function.

The following description sets forth the general procedures involved in practicing the present invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. Unless otherwise specified, general cloning procedures, such as those set forth in Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989) (hereinafter "Sambrook et al.") are used.

I. Preparation of nucleic acid molecules, CENP-F proteins and antibodies thereto

A. Nucleic Acid Molecules

Nucleic acid molecules encoding CENP-F proteins of the invention may be prepared by two general methods: (1) They may be synthesized from appropriate nucleotide triphosphates, or (2) they may be isolated from biological sources. Both methods utilize protocols well known in the art.

The availability of nucleotide sequence information, such as the full length cDNA having Sequence I.D. No. 2, enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Synthetic oligonucleotides may be prepared by the phosphoramadite method employed in the Applied Biosystems 38A DNA Synthesizer or similar devices. The resultant construct may be purified according to high performance liquid chromatography (HPLC). Long, double-stranded polynucleotides, such as a DNA molecule of the present invention, must be synthesized in stages, due to the size limitations inherent in current oligonucleotide synthetic methods. Thus, for example, a 10.1-kb double-stranded DNA molecule may be synthesized as several smaller segments of appropriate complementarily. Complementary segments thus produced may be annealed such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire 10.1-kb double-stranded molecule. A synthetic DNA molecule so constructed may then be cloned and amplified in an appropriate vector.

Nucleic acid sequences encoding CENP-F may be isolated from appropriate biological sources using methods known in the art. In a preferred embodiment, a cDNA clone is isolated from an expression library of human origin. In an alternative embodiment, human genomic clones encoding CENP-F may be isolated. Alternatively, cDNA or genomic clones encoding CENP-F from other species may be obtained.

In accordance with the present invention, nucleic acids having the appropriate level sequence homology with the protein coding region of Sequence I.D. No. 2 may be identified by using hybridization and washing condition of appropriate stringency. For example, hybridizations may be performed, according to the method of Sambrook et al., using a hybridization solution comprising: 5×SSC, 5×Denhardt's reagent, 1.0% SDS, 100 μg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37°-42° C. for at least six hour. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2×SSC and 1% SDS; (2) 15 minutes at room temperature in 2×SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37° C. in 1×SSC and 1% SDS; (4) 2 hours at 42°-65° in 1×SSC and 1% SDS, changing the solution every 30 minutes.

Nucleic acids of the present invention may be maintained as DNA in any convenient cloning vector. In a preferred embodiment, clones are maintained in plasmid cloning/expression vector, such as pBluescript (Stratagene, La Jolla, Calif.), which is propagated in a suitable E. coli host cell.

CENP-F-encoding nucleic acid molecules of the invention include cDNA, genomic DNA, RNA, and fragments thereof which may be single- or double-stranded. Thus, this invention provides oligonucleotides (sense or antisense strands of DNA or RNA) having sequences capable of hybridizing with at least one sequence of a nucleic acid molecule of the present invention, such as selected segments of the cDNA having Sequence I.D. No. 2. Such oligonucleotides are useful as probes for detecting CENP-F genes in test samples, e.g. by PCR amplification, or as potential regulators of gene expression.

B. Proteins

A full-length CENP-F protein of the present invention may be prepared in a variety of ways, according to known methods. The protein may be purified from appropriate sources, e.g., human or animal cultured cells or tissues, by immunoaffinity purification using autoimmune serum. However, due to the limited amount of CENP-F present in a sample at any given time, conventional purification techniques are not preferred in the present invention.

The availability of nucleic acids molecules encoding CENP-F enables production of the protein using in vitro expression methods known in the art. For example, a cDNA or gene may be cloned into an appropriate in vitro transcription vector, such a pSP64 or pSP65 for in vitro transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocytes. In vitro transcription and translation systems are commercially available, e.g., from Promega Biotech, Madison, Wis. or BRL, Rockville, Md.

Alternatively, according to a preferred embodiment, larger quantities of CENP-F may be produced by expression in a suitable procaryotic or eucaryotic system. For example, part or all of a DNA molecule, such as the cDNA having Sequence I.D. No. 2, may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as E. coli, or into a baculovirus vector for expression in an insect cell. Such vectors comprise the regulatory elements necessary for expression of the DNA in the bacterial host cell, positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include promoter sequences, transcription initiation sequences and, optionally, enhancer sequences. An example of a useful procaryotic expression vector for expressing DNA molecules of the invention is described in Example 1.

The CENP-F produced by gene expression in a recombinant procaryotic or eucyarotic system may be purified according to methods known in the art. In a preferred embodiment, a commercially available expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein. Such methods are commonly used by skilled practitioners.

The CENP-F proteins of the invention, prepared by the aforementioned methods, may be analyzed according to standard procedures. For example, such proteins may be subjected to amino acid sequence analysis, according to known methods.

The present invention also provides antibodies capable of immunospecifically binding to proteins of the invention. Polyclonal antibodies directed toward CENP-F may be prepared according to standard methods (see Example 1). In a preferred embodiment, monoclonal antibodies are prepared, which react immunospecifically with various epitopes of CENP-F. Monoclonal antibodies may be prepared according to general methods of Kohler and Milstein, following standard protocols. Polyclonal or monoclonal antibodies that immunospecifically interact with CENP-F can be utilized for identifying and purifying such proteins. For example, antibodies may be utilized for affinity separation of proteins with which they immunospecifically interact. Antibodies may also be used to immuoprecipitate proteins from a sample containing a mixture of proteins and other biological molecules. Other uses of anti-CENP-F antibodies are described below.

II. Uses of CENP-F-Encoding Nucleic Acids, CENP-F Proteins and Antibodies Thereto

Cell proliferative activity has recently received a great deal of attention as a prognostic indicator of neoplastic disease. The measurement of tumor cell proliferation in particular yields a variety of useful data for tumor diagnosis, classification and prognosis. Accordingly, cell cycle-specific markers have become increasingly valuable for clinical and pathological applications. Because CENP-F is specifically detected mainly in the G2 and M phases of the cell cycle, CENP-F promises to be a particularly useful cell cycle-specific marker for assessing proliferative activity in various biological samples.

A. CENP-F-Encoding Nucleic Acids

CENP-F-encoding nucleic acids may be used for a variety of purposes in accordance with the present invention. For monitoring cellular proliferation in vitro or in vivo, CENP-F-encoding DNA, RNA, or fragments thereof, may be used as probes to detect the presence and/or expression of genes encoding CENP-F. Methods in which CENP-F-encoding nucleic acids may be utilized as probes for assays of cellular proliferation include, but are not limited to: (1) in situ hybridization; (2) Southern hybridization; (3) Northern hybridization; and (4) assorted amplification reactions, such as polymerase chain reaction (PCR).

The CENP-F-encoding nucleic acids of the invention may also be utilized as probes to identify related genes either from humans or from other species. As is well known in the art, hybridization stringencies may be adjusted so as to allow hybridization of nucleic acid probes with complementary sequences of varying degrees of homology. Thus, CENP-F-encoding nucleic acids may be used to advantage to identify and characterize other genes, of varying degrees of relation to CENP-F, which may encode proteins functioning in cell division.

As described above, CENP-F-encoding nucleic acids are also used to advantage to produce large quantities of substantially pure CENP-F protein, or selected portions thereof. Due to the scarcity of CENP-F protein in biological tissues at any given time, expressible cDNA encoding CENP-F provide a much-needed source of the protein for use as a diagnostic tool to assess cellular proliferation.

B. CENP-F Protein and Antibodies

As discussed above, and in greater detail in Example 2, studies on human patients have indicated that a relationship may exist between the presence of autoantibodies to CENP-F and diseases involving malignancy. Accordingly, purified CENP-F also may be labelled and used as a sensitive detection reagent to detect the presence and amount of anti-CENP-F autoantibodies from a blood or tissue sample of patients suspected of having a malignancy-related disease.

Purified CENP-F, or fragments thereof, may be used to produce polyclonal or monoclonal antibodies which themselves may serve as sensitive detection reagents for the presence and accumulation of CENP-F in cultured cells or in tissues from living patients. Recombinant techniques enable expression of fusion proteins containing part or all of the .ca 372 kDa CENP-F protein. The full-length protein or fragments of the protein may be used to advantage to generate an array of monoclonal antibodies specific for various epitopes of the protein, thereby potentially providing even greater sensitivity for detection of the protein in cells or tissues.

Polyclonal or monoclonal antibodies immunologically specific for CENP-F may be use in a variety of assays designed to measure cellular proliferation and thereby diagnose or render a prognosis as to a malignant disease. Such assays include, but are not limited to: (1) flow cytometric analysis; (2) immunochemical localization of CENP-F in cultured cells or tissues; and (3) immunoblot analysis (e.g., dot blot, Western blot) of extracts from various cells and tissues. Additionally, as described above, anti-CENP-F antibodies can be used for purification of CENP-F (e.g., affinity column purification, immunoprecipitation).

From the foregoing discussion, it can be seen that CENP-F-encoding nucleic acids, proteins and antibodies thereto can be used to detect CENP-F gene expression, proteins and autoantibodies for purposes of assessing cellular proliferation in a tissue sample. It is expected that these tools will be particularly useful for diagnosis and prognosis of human neoplastic diseases. However, one skilled in the art will appreciate that these tools will also be useful in animal and culture cell experimentation with respect to various malignancies. They can be used to monitor the effectiveness of potential anti-cancer agents on cellular proliferation in vitro, and/or the development of neoplasms or other malignant diseases in animal model systems.

The following examples are provided to describe the invention in further detail. These examples are intended to illustrate and not to limit the invention.

EXAMPLE 1 Cloning and Expression of a cDNA Encoding CENP-F and Analysis of the Recombinant Protein

In this example, we describe the cloning of a cDNA molecule encoding human CENP-F, and provide and analysis of the structure of CENP-F as predicted from the deduced amino acid sequence encoded by the cDNA. Additionally, we describe the production of antibodies immunospecific for the recombinant CENP-F protein, and their use in immunological detection of transient expression of CENP-F in synchronously dividing cells.

Materials and Methods

Cell culture and synchronization

HeLa cells were grown at 37° C. in DMEM supplemented with 10% FCS and antibiotics. Synchronization of cells at the G1/S phase was performed by successive thymidine/aphidocolin blocks. Cells were released from the blocks by washing in warm PBS and replacing the growth media. Cell synchrony was monitored by flow cytometry. For pulse labelling, cells were starved in cys- and met- media for 20 minutes before addition of TranSlabel (200 uCi/ml, ICN Biomedicals, Inc., Costa Mesa, Calif.) and 5% dialyzed FCS. Cells were labelled for 10 minutes before harvesting for immunoprecipitations. For pulse-chase experiments, cells that were pre-synchronized at either the G1/S or in G2 were labelled for 30 minutes, washed, and then chased for 1,2, and 4 hours in cold media. Pulse-chase of G2 cells was performed either in the presence of absence of 0.1 μg/ml colcemid (Sigma Chemical Co., St Louis). For BudR labelling, cells that were synchronized at various stages of the cell cycle were incubated in the presence of 10 μM BudR for 15 minutes before processing for detection.

cDNA cloning and sequencing

5×105 phage from a lamdba gt11 human breast carcinoma cDNA expression library (Clontech, Palo Alto, Calif.) was screened with autoimmune serum (Rattner et al., 1993, supra) by following published protocols (Sambrook et al., 1989). Briefly, protein expression was induced by laying IPTG soaked nitrocellulose filters (Millipore Corp., Bedford, Mass.) on the surface of the top agar. After 4 hours at 37° C., filters were removed, rinsed, blocked and incubated overnight at 4° C. with serum (1:500 dilution). Filters were washed the next morning, and bound antibodies were detected with 125 -protein A (ICN). Positive plaques were eluted and rescreened with the autoimmune serum until single plaques were identified. For plaque hybridizations, 3×106 plaques from the same cDNA library were screened with a 300 bp EcoRI and HindIII fragment that was derived from the 5' end of clone D7 (FIG. 1). Probes were labelled to high specific activity with α32 P dCTP (Amersham, Arlington Heights, Ill.) by random priming. Filters were hybridized at 60° C. in buffer (5×SSPE, 5×Denhardt's, 0.5% SDS, 100 μg/ml of sonicated herring sperm DNA and torula RNA) with 2 to 3×106 cpm/ml of probe. Filters were washed a high stringency (65° C. in 0.2× SSC, 0.1% SDS for 20 minutes) before exposing to X-ray film.

cDNAs were isolated from the recombinant phage DNA by either EcoRI or BsiWI digestion, subcloned into the EcoRI and Acc65I sites respectively, in either the vectors M13 mp18 or pBluescript SK. 5'RACE (Clontech) was performed on HeLA polyA+ mRNA to isolate the 5' end of the CENP-F cDNA. To increase specificity, nested primers 5'-CTTTTGCTTTCTCCAGTTGG-3' (Sequence I.D. No. 3) and 5-TTGACGCCTGGTCGTATTG-3', (Sequence I.D. No. 4) respectively were used for the RT-PCR. The complete cDNA was determined from both strands by sequencing overlapping restriction fragments. DNA sequencing was performed with Sequenase v2.0 (U.S. Biochemicals, Cleveland, Ohio). Compilation and analysis of the of the DNA sequences were performed either with MacVector (Kodak, New Haven, Conn.) or GCG (University of Wisconsin).

Northern blots

2 to 3 μg of HeLa polyA+ mRNA that was isolated from cells enriched in the G2 stage of the cell cycle was separated by agarose gel electrophoresis, transferred onto Hybond N (Amersham) and processed according to manufacturer's instructions. EcoRI fragments derived from each phage clone were used to probe the filters using the hybridization conditions described above.

Expression of bacterial fusion protein and generation of CENP-F antibodies

cDNA fragments (derived from clones 7, 8 and 10 shown in FIG. 1) that spanned different portions of CENP-F (from nucleotide 3420 to 6408, 6992 to 7538, and 8445 to end) were subcloned into the EcoRI site of the expression vector pMAL (New England Biolabs, Beverly, Mass.) and transformed into E. coli strain CAG456. Protein expression was induced with 1 mM IPTG when cultures reached an O.D. of 0.6. After 4 hours at 30° C., bacteria were harvested, washed and sonicated. The supernatant (S30 fraction) that contained the fusion protein was immediately frozen or boiled in the presence of SDS sample buffer, and the proteins separated by PAGE. Fusion protein was sliced from the gel after staining in 0.1% Coomassie Brilliant Blue and 40% methanol. For immunization, the gel slices were macerated and directly injected into rabbits. Typically, each rabbit was injected with 100 to 200 μg of fusion protein and boosted twice (2 to 3 weeks between boosts) before serum was tested by immunofluorescence staining or immunoblotting. Rabbit IgG was purified by ion exchange chromatography, concentrated by (NH2)2 SO4 precipitation, dialyzed in PBS and stored at approximately 5 to 10 mg/ml.

Immunodetection methods

For immunofluorescence staining, HeLa cells growing on 18 mm coverslips were fixed at room temperature for 7 minutes in 4% paraformaldehyde buffered in PBS at pH 6.8, extracted for 5 minutes in KB (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% BSA)+0.2% Triton X-100, rinsed in KB for 10 minutes and then incubated with CENP-F antibodies in a 37° C. humidified chamber. After 30 minutes, coverslips were washed in KB for 10 minutes and re-incubated with biotinylated goat anti-rabbit (1 μg/ml, Gibco BRL, Gaithersburg, Md.) for 30 minutes, followed by incubation in streptavidin-Texas Red and DAPI. If simultaneous detection of bromodeoxyuridine (BrdU) was desirable, the coverslips with the antibody sandwich were re-fixed for 5 minutes in 4% paraformaldehyde/PBS, rinsed in water before submerging into 4M HCl for 10 minutes (the acid treatment also eliminated DAPI staining). After extensive washing, the coverslips were blocked in KB for 10 minutes before incubating with an anti-BrdU monoclonal antibody (1:20, Boerhinger Mannheim Biochemicals). Monoclonal antibody was detected with FITC-coupled goat anti-mouse IgG (10 μg/ml, Gibco). All the samples were mounted in 90% glycerol containing paraphenylenediamine and observed with a Nikon Microphot SA microscope equipped for epifluorescence optics. Images were observed with a 100× Plan Neofluor objective and photographs were recorded on Tmax400 film (Kodak).

Immunoprecipitations were performed by incubating polyclonal CENP-F antibodies (1:200) with HeLa cell lysates at 4° C. for several hours. Immunocomplexes were precipitated with 40 μl of a 1:1 slurry of protein A-sepharose beads (Pharmacia, Picataway, N.J.). Immunoprecipitates were boiled in SDS sample buffer and separated by SDS PAGE. For detection of 35 S-labelled proteins, the gels were fixed and enhanced before exposing to X-ray film (Kodak XAR). For Western blot analysis, the separated proteins in the gels were transferred onto Immobilon P (Millipore), blocked, incubated with anti-CENP-F antibodies as described (Rattner et al., 1993, supra). Bound antibodies were detected with 125 I-protein A (ICN).

Results

Cloning of CENP-F cDNA

We isolated ten immunopositive phage clones (D1 through D10 shown in FIG. 1) after screening a cDNA expression library with the autoimmune serum that contained CENP-F antibodies. Initial restriction mapping and sequence analysis of these clones revealed that they were all related with exception of clone D5 which was not further characterized. Clones D7, D8 and D10 overlapped one another and spanned 8.3 kb of contiguous DNA that included a polyadenylation sequence as well as a homopolyA tract at the 3' end of clone D10. Since all three clones contained multiple EcoRI fragments, we considered whether they might be derived from the same mRNA by using each fragment to probe HeLa polyA+ mRNA by Northern blot analysis. Consistent with this possibility, all of the fragments hybridized to a single, 10 to 11 kb RNA that was of the appropriate size to encode the estimated 400 kDa CENP-F protein.

Exhaustive screening of the DNA library by plaque hybridization yielded a single clone ("7-1" in FIG. 1) that extended the cDNA by about 0.75 kb toward the 5' end. Since the open reading frame that was derived from the 9 kb of contiguous DNA sequences was insufficient to account for full-length CENP-F, 5'RACE was used to attempt to extend the DNA toward the 5' end of the CENP-F mRNA. Based on our finding that the CENP-F mRNA was most abundant during the G2 stage of the cell cycle, we isolated polyA+ mRNA derived from this timepoint and used nested oligonucleotide primers that were near the 5' end of the existing cDNA for RT-PCR. PCR products that extended the cDNA by another 1.1 kb were obtained. DNA sequence of several independent PCR clones revealed that we had isolated two PCR-extension products that differed only in that the 5' end of one fragment was 42 base pairs longer than the other. The shorter PCR product is presumably derived from a prematurely terminated product from the first-strand synthesis reaction. Inspection of the complete 10,130-bp CENP-F cDNA revealed that, if translation initiated at nucleotide position 171, a polypeptide of 3248 amino acids with an estimated mass of 372 kDa would be produced. Given that no extended ORF's were present upstream of this ATG and that the calculated mass is close the estimated size of 400 kDa, we concluded that the complete coding sequence of CENP-F was cloned.

Authentication of the CENP-F cDNA

The authenticity of the initial cDNA clones was also validated. To verify whether the original phage clones encoded CENP-F, three non-overlapping cDNA fragments derived from clones D7, D8 and D10 (FIG. 1) were subcloned into the expression vector pMAL for protein expression in bacteria. Analysis of the proteins expressed after induction revealed that all three fragments expressed a fusion protein of the appropriate size (172 kDa, 82 kDa and 96 kDa) and were recognized by the autoimmune serum. Sera from immunized rabbits that recognized the injected fusion proteins by immunoblot analysis were subsequently tested for their ability to recognize the authentic CENP-F protein. Since identical results were obtained with all three sera, only antibodies raised against the D10 fusion protein were used for subsequent studies. Western blot analysis of HeLa mitotic cell lysates showed that, while the pre-immune antibodies failed to detect a protein of the size of CENP-F, the D10 antibodies identified a large molecular weight protein that shared very similar electrophoretic mobility with authentic CENP-F. Furthermore, the ability of the antibodies to recognize CENP-F-containing immunoprecipitates confirmed that the cDNAs encoded epitopes that are shared with CENP-F.

We next examined the immunofluorescence staining patterns produced by the antibodies in a population of synchronously growing HeLa cells. Pre-immune sera incubated under identical conditions as the immune sera produced only background staining. On the other hand, the D10 antibody produced a staining pattern that was nearly identical with that obtained with the autoimmune serum (Rattner et al, 1993, supra). As was the case for the autoimmune serum, the majority of interphase cells did not exhibit D10 antibody staining that was significantly above background. However, a small percentage (15 to 20%) of interphase cells, presumably at late stages of their cell cycle, exhibited bright nuclear staining. At prophase, when the chromatin begins to condense, a double-dot staining pattern, which probably reflects the staining of the centromere-kinetochore complex, was detected. Staining of the centromere-kinetochore region was most prominent in prometaphase and metaphase. As cells progressed into anaphase, staining of the centromere-kinetochore complex was still detectable, although at reduced intensities. Late in anaphase, staining was relatively diffuse throughout the cell with the exception of a distinct, narrow stripe of staining confined at the spindle equator. The narrow stripe of staining is presumably concentrated to both sides of the midbody as a result of cleavage furrow formation during cytokinesis. The ability of antibodies produced from three non-overlapping regions of the cDNA to produce nearly the identical staining pattern as seen with the autoimmune serum, coupled with their ability to recognized authentic CENP-F by immunoblot analysis, confirms that we had successfully cloned proteins of the CENP-F cDNA.

Structural Analysis of Recombinant CENP-F

Comparison of the primary sequence of CENP-F with either FASTA or BLAST (both publicly available sequence analysis databases) did not reveal any significant homologies with other known proteins. However, CENP-F consistently exhibited a low level of homology (<20%) with the rod domains of many cytoskeletal proteins such as myosins, kinesins, lamins and tropomyosins that probably reflects similarities in secondary structure. Analysis of the CENP-F amino acid sequence with the COILS2 program (public software) revealed that residues 1 to 200, 280 to 1350, 1620 to 1750, 1850 to 2990 exhibited high probabilities of forming an extended coiled structure. Located in between the two largest coil domains, from 1380 to 1610, is a putative globular domain that consists of two direct repeats of 95 amino acids. The COOH-terminal 200 amino acids is predicted to form a globular domain that is highly basic (pI of 10) and proline-rich(10.6%). Consistent with its nuclear localization, several consensus nuclear localization sequences are found within the NH2 and COOH-terminal 200 amino acids. Additionally, clusters of consensus phosphorylation sites for either MAP kinases or cyclin-dependent kinases (cdk) are present within both the terminal domains. Finally, a consensus P-loop nucleotide binding site (A/GXXXXGKS/T) is located within the COOH terminus.

The general organization of the CENP-F protein is highly similar to the newly discovered SMC family of chromatin compaction proteins. The SMC proteins have two long extended coil domains that flank a central core domain. Within the NH2 terminal domains of the SMC family members, there is a conserved P-loop consensus, as well as similarity within the surrounding 59 residues. Likewise, SMC family members share a helix-loop-helix domain within the COOH terminus.

Although CENP-F protein does not appear to exhibit any significant sequence homologies with other known proteins, its predicted secondary structure reveals a tripartite organization consisting of a head, extended rod and tail domains that bears striking resemblance to the SMC family of chromosome condensation proteins. Like all SMC family members, the central domain of CENP-F consists of two extended coil-coil domains that are separated by a spacer region. Although CENP-F possesses a NTP-binding site that is conserved amongst all the SMC family members, it is located within its COOH-terminal globular domain instead of at the NH2 terminus. This difference, coupled with the absence of a conserved helix-loop-helix domain in CENP-F suggests that it may be only a distant relative of the SMC family.

Analysis of CENP-F expression during the cell cycle

Previous data as well as the results reported here show that CENP-F is a nuclear protein that is detected in only some interphase cells. To monitor when CENP-F is detectable during the cell cycle, we stained HeLa cells that were synchronized at different portions of the cell cycle. Examination of early G1 cells that were obtained several hours after replating a population of mechanically disloged mitotic cells did not produce detectable levels of CENP-F. Likewise, CENP-F was not detectable in cells that were arrested at the G1/S boundary. One hour after releasing cells from the G1/S boundary, faint CENP-F staining was detected in the nuclei that were replicating DNA as monitored by BrdU incorporation. Staining intensity increased gradually as cells progressed through S phase and reached the brightest levels during G2.

To obtain quantitative data on the cell cycle expression pattern of CENP-F, we measured the steady-state levels of CENP-F in cells that were synchronized at various parts of the cell cycle. Consistent with the absence of CENP-F staining in G1 cells, immunoblot analysis did not detect CENP-F in cells that were synchronized at the G1/S boundary. CENP-F steady-state levels gradually accumulated as cells progressed through S phase and reached peak levels at G2 and M. Steady-state levels dropped dramatically when cells completed mitosis and reentered G1. Consistent with the increase in the steady-state levels, there was a moderate increase in the synthesis rate of CENP-F between cells blocked at the G1/S boundary and G2 cells. We compared the turnover rate of CENP-F at different points in the cell cycle to determine whether there was an accelerated decay of CENP-F in cells progressing through mitosis. The average t1/2 was reduced to approximately 1.8 hours. This is likely still an overestimate since the last time point in G1 commonly is contaminated with a small (˜15%) but significant fraction of mitotic cells that contain stable pulse-labelled CENP-F. In a parallel pulse-labelled culture that was blocked from completing mitosis by chasing them in media containing colcemid, CENP-F was undegraded. Thus, the accelerated degradation of CENP-F is dependent upon the cells' ability to progress through mitosis.

EXAMPLE 2 Association of Circulating CENP-F AutoAntibodies with Malignancy and Assessment of CENP-F

Distribution in Malignant and Non-Malignant Tissues

The mammalian centromere is a multi-functional chromosomal domain that plays a major role during cell proliferation mediating both chromosome movement and sister chromatid association. Six unique mammalian CENtromere Proteins (CENP) have been identified and at least five (CENP A, B, C, D and F) are target antigens in autoimmune diseases. Of the six centromere proteins, four (CENP-A, B, C, and D) are found in association with the centromere throughout the cell cycle. The remaining two (CENP-E and F), are found only at the centromere during the latter stages of the cell cycle. The ability of CENP-F antibodies to allow the specific detection of G2 and M-phase cells in tissue culture cells enables CENP-F to be a useful addition to the list of cell cycle specific markers used to study cell proliferation in tumor samples.

The studies set forth in this Example were undertaken to gather more information about the relationship between individuals possessing autoantibodies to CENP-F and the development of malignant disease, and to determine if this antigen is present in malignant tissues.

Materials and Methods

Serum and Clinical Information Collection

Eight sera containing autoantibodies to CENP-F were first detected by indirect immunofluorescence using a commercially available Hep-2 cell substrate (Immuno Concepts Inc., Sacramento, Calif.). These sera displayed a typical pattern of CENP-F staining. Reactivity within the .ca 400 kDa region of immunoblots was confirmed using HeLa cell protein, following the procedure described by Rattner et al., 1993, supra. The clinical information was obtained retrospectively.

Specimen Collection

Cryopreserved tissue samples were collected through the Histopathology Department of the Foothills Hospital, Calgary, Alberta, Canada from unselected patients undergoing radical mastectomy or reduction mammoplasty. All breast cancer specimens described herein were determined to have ductual carcinoma using standard pathological criteria. Specimens of tonsil were collected from routine tonsillectomies. Samples were quick frozen and frozen section were cut and stored at -20° C. until use.

Two cell lines of breast tumor origin (HTB 30 and HTB 132), originally obtained from the American Type Tissue Collection, were a gift from Drs. Don Fujita and Karl Riabowol, The University of Calgary. Both HTB 30 and HTB 132 were derived from a breast adenocarcinoma. The cells were grown in Joklik's suspension medium supplemented with 10% fetal calf serum. Forty-eight hours prior to use, cells were seeded onto coverslips.

Indirect Immunofluorescence (IIF)

Frozen sections or monolayer cultures of tissue culture cells grown on coverslips were fixed for 10 minutes in 3% paraformaldehyde in Dulbecco's phosphate buffered saline (D-PBS). Fixed preparation were washed in D-PBS and then incubated for 1 hour at 37° C. in a 1:100 dilution of a CENP-F antiserum, as described by Rattner et al., 1993 supra. For double label experiments, specimens were incubated in a mixture of the CENP-F serum at a dilution of 1:100 and commercially available mouse monoclonal antibody to Ki-67 (Dakopatts) at a dilution of 1:50. In some experiments a human autoimmune serum containing antibodies to the centrosome were used at a dilution of 1:50. The characterization of this serum has been previously reported (Rattner, et al., J. Immunol. 146: 2341-2344, 1991).

Following three washes in D-PBS, the samples were incubated for one hour at 37° C. in secondary antibody: a fluorescein conjugated anti-human IgG(H+L) (Dakopatts) and/or a rhodamine conjugated anti-mouse IgG(H+L) (Dakopatts). After incubation, the specimens were washed in D-PBS, counterstained with DAPI (4',6-diamindino-2-phenylidole), and mounted in 90% glycerol containing paraphenylenediamine and observed using a Nikon Optophot flourescence microscope. Images were recorded on Ilford HP-5 film.

Immunoblotting

Imunoblotting was performed on nitrocellulose strips containing proteins from a breast tumor sample and cells harvested from log phase cultures of HTB 30 and HTB 132 cultures. Proteins from cell lysates ware separated by 4% SDS polyacrylamide gel electrophoresis. The whole cell protein extracts used for the immunoblots were obtained by suspending tissue fragments or tissue culture cells detached from monolayer cultures by trypsin digestion in SDS sample buffer, followed by sonication. Antibody binding to nitrocellulose strips was detected using enhanced chemiluminescence (ECL, Amersham). The anti-CENP-F serum was used at a dilution of 1:100.

RESULTS

The clinical diagnosis and demographic features of 8 patients with antibodies to CENP-F are shown in Table 1.

              TABLE 1______________________________________Clinical Features of Patients with CENP-F AntibodiesPatient Age     Gender   Primary Complaints                               Diagnosis______________________________________1     72      F        Fever        Prolactinoma,                               Hepatitis2     72      F        Arthralgia   BRC3     75      M        Fever, arthritis                               SCLC4     58      M        Arthritis, dyspnea                               SCLC5     50      F        Arthritis, fever                               OVC6     64      M        Arthritis, vasculitis                               SCLC7     76      F        Arthralgia, Myalgia,                               BRC                  hemoptysis8     46      F        Arthralgia   None______________________________________ Abbreviations: BRC = breast carcinoma, OvC ovary carcinoma, SCLCsmall cel lung carcinoma.

As shown in Table 1, three patients were males and 5 were females. The age range was 46 to 76 years (mean 64 years). Four patients presented with complaints of arthritis but did not fulfill the American College of Rheumatology criteria for rheumatoid arthritis. Other patients' symptoms included fever of unknown origin (n=3), arthralgia (n=3), myalgia (n=1), hemoptysis (n=1) and dyspnea (n=1). Six patients were subsequently found to have a malignancy. Four had small cell lung carcinoma, two had carcinoma of the breast and one carcinoma of the ovary. One patient had a prolactinoma and abnormal liver function tests but did not have laboratory evidence for infectious disease. One patient had a retinal vasculitis and another patient did not have a definitive diagnosis.

The presence of autoantibodies to CENP-F in patients with carcinomas raised the question of the possible source of the autoantigen. To determine if CENP-F is expressed in proliferating cells of tumor and/or nontumor origin, we first reacted CENP-F antibodies with a frozen section of tonsil (as an example of nontumor tissue) and counterstained for DNA with DAPI. Reactivity was detectable in small population of cells. In this population, reactivity was either seen throughout the nucleus, a pattern characteristic of G2 cells, or as a series of paired punctuate spots in regions containing clusters of chromosomes. Cells in the latter stages of cell division were not observed in our tissue samples.

Since some individuals in the CENP-F patient group had breast carcinoma, and since breast tumor tissue and breast cancer cell lines were readily available, we chose this tumor type as a prototype to study CENP-F distribution in malignant tissue. For comparative purposes, CENP-F antibodies were first reacted with monolayers of two breast carcinoma cell lines, HTB-30 and HTB-132, and examined by IIF. Both cells lines showed a pattern of reactivity similar to that documented for CENP-F in HeLa and Hep-2 cell lines. That is, within the reactive cell population, several types of patterns could be detected. In the first, reactivity was seen throughout intact nuclei. Cells with maximum reactivity displaying this IIF pattern were double stained with antibodies to the centrosome; these cells displayed duplicated and separated centrosomes. This pattern is characteristic of cells in the G2-M-phase transition. The second pattern of CENP-F reactivity was confined to cells that displayed recognizable chromosomes. In these cells, the CENP-F reactivity was confined to small punctate regions and generally appeared as paired spots. Finally, examination of anaphase and telophase cells revealed the final relocation of the CENP-F antigen to the spindle midzone in a region lateral to the midbody. Western blot analysis of proteins derived from both breast cancer cell lines using the CENP-F serum confirmed the presence of the CENP-F antigen.

To determine the percent of actively proliferating cells displaying detectable CENP-F antigen, in breast cancer cells line as compared to HeLa cells, five-hundred cells were scored for both Ki-67 and CENP-F reactivity. Monolayer cultures that had reached semi-confluency 48 hours after plating onto coverslips were used for each cell line. Results are shown in Table 2.

              TABLE 2______________________________________     % Ki-67    % CENP-F   % Ki-67 cells     reactive   reactive   also reactiveCell Type cells      cells      with CENP-F______________________________________HeLa      91%        9%          9%HTB-30    46%        9%         18%HTB-132   87%        13%        15%______________________________________

As shown in Table 2, strongly staining CENP-F reactive cells represent a small subpopulation of cycling cells within each cell line as indicated by Ki-67 reactivity. The proportion of this population is similar in the cell lines of breast cancer origin, irrespective of the percent of cycling cells, and is greater than that found in HeLa cells. In all cell lines, CENP-F reactive cells were always found to be Ki-67 positive.

To determine if the CENP-F pattern seen in the breast carcinoma cell lines was also detectable in tumor tissue samples, double label experiments were carried out using antibodies to Ki-67 and CENP-F on cryopreserved sections of breast cancer tissue counterstained with DAPI. When detected, CENP-F reactive cells represented a minor population of Ki-67 reactive cells seen within a variety of tumor samples. In many samples abundant Ki-67 cells were observed, with no detectable CENP-F population.

Within samples displaying CENP-F reactive cells, two distinct patterns of reactivity were seen. In the first, CENP-F reactivity was found throughout the nucleus, a pattern characteristic of G2 cells. In the second, the CENP-F pattern appeared punctate. In cells displaying this pattern, the corresponding DAPI image revealed distinct chromosomes and the corresponding Ki-67 images displayed a halo pattern characteristic of the prometaphase-metaphase staining pattern produced by this antibody due to its localization to the surface of the chromosome. Neither Ki-67 nor CENP-F reactive cells were observed in cryosection of tissue obtained from reduction mammoplasties.

The number and pattern of Ki-67 and CENP-F reactive cells varied both between tissue samples and within regions of a single section. In some regions, or samples, CENP-F reactive cells occurred singly, while in others, clusters of positive cells could be detected which generally displayed the G2 pattern of reactivity. When samples displaying clusters of CENP-F reactive cells were stained with anti-centrosome antibodies, it was possible to observe duplicated and separated centrosomes adjacent to the reactive nuclei. This centrosomal pattern was consistent with the suggestion made by the CENP-F pattern that these cells are in the latter stages of the cell cycle immediately preceding mitosis. We were unable to detect CENP-F in Western blots prepared from tissue samples showing CENP-F reactivity by IIF. This likely reflects the relatively small population of cells expressing CENP-F in the total cell population present in the tissue sample.

Discussion

All of the patients described in this Example sought medical advice after the onset of constitutional rheumatic disease symptoms and 6/8 were subsequently found to have a malignancy. In the last decade, there has been a growing interest in autoantibodies in malignancy, some of which are used as markers of paraeoplastic syndromes. For example, antibodies to the cytoplasmic antigen Yo serve as a marker for paraneoplastic cerebellar degeneration in patients with breast or ovarian cancer (Peterson et al., Neurology 42: 1931-1937, 1992). Antibodies to the nuclear antigen Hu are a marker for paraneoplastic encephalomyelitis in patients with small cell lung cancer and other malignancies (Dalmau et al., Ann. Neurol. 27 544-552, 1990). The pattern of staining and the molecular weight of the CENP-F antigen distinguish it from previously described autoantibodies associated with paraneoplastic syndromes.

It is clear from numerous studies of cancer that there is a relationship between the degree of cellular proliferation and prognosis, and this is also true in the case of mammary carcinomas. In general, higher proliferation rates are found in malignant tumors and only rarely in benign tumors. In malignant tumors, high proliferation rates are associated with a poorer prognosis and response to radiotherapy or chemotherapy than neoplasms with lower proliferation rates. Mitotic counts from conventional hematoxylin and eosin sections have enjoyed the most general acceptance for the determination of proliferation in surgical pathology. However, this approach has the drawback that such counts may be subjective and may not be reproducible. In addition, fixation of sections can affect the number of mitoses observed.

In contrast to other procedures, immunohistochemical procedures offer the advantage of negligible tissue consumption and of in situ analysis which allows differentiation of proliferating tumor cells from stromal cell populations. Recently, a number of markers of cell proliferation useful in detecting and quanititating proliferating cells have been described. These markers generally react with cells throughout the cell cycle and do not allow one to distinguish specific stages in the cell cycle with ease. In the present study we provide evidence that a cell cycle-specific centromere protein, CENP-F, allows the direct visualization and discrimination of a subpopulation of cycling cells (G2 and M-phase populations) in frozen section of normal and malignant tissues. The availability of this probe makes it possible to extract precise cell cycle information directly from cytological specimens.

While certain embodiments of the present invention have been described and exemplified above as preferred embodiments, various other embodiments should be apparent to those skilled in the art from the foregoing disclosure. The present invention, therefore, is not limited to the embodiments specifically described and exemplified above, but is capable of variation and modification within the scope of the appended claims.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 4(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 3248 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:MetSerTrpAlaLeuGluGluTrpLysGluGlyLeuProThrArgThr151015LeuGlnLysIleGlnGluLeuGluGlyGlnLeuAspLysLeuLysLys202530GluLysGlnGlnArgGlnPheGlnLeuAspSerLeuGluAlaAlaPro354045GlnLysGlnThrGlnLysValGluAsnGluLysThrGluGlyThrAsn505560LeuLysArgGluAsnGlnArgLeuMetGluIleCysGluSerLeuGlu65707580LysThrLysGlnLysIleSerHisGluLeuGlnValLysGluSerGln859095ValAsnPheGlnGluGlyGlnLeuAsnSerGlyLysLysGlnIleGlu100105110LysLeuGluGlnGluLeuLysArgCysLysSerGluLeuGluArgSer115120125GlnGlnAlaAlaGlnSerAlaAspValSerLeuAsnProCysAsnThr130135140ProGlnLysIlePheThrThrProLeuThrProSerGlnTyrTyrSer145150155160GlySerLysTyrGluAspLeuLysGluLysTyrAsnLysGluValGlu165170175GluArgLysArgLeuGluAlaGluValLysAlaLeuGlnAlaLysLys180185190AlaSerGlnThrLeuProGlnAlaThrMetAsnHisArgAspIleAla195200205ArgHisGlnAlaSerSerSerValPheSerTrpGlnGlnGluLysThr210215220ProSerHisLeuSerSerAsnSerGlnArgThrProIleArgArgAsp225230235240PheSerAlaSerTyrPheSerGlyGluLeuGluValThrProSerArg245250255SerThrLeuGlnIleGlyLysArgAspAlaAsnSerSerPhePheGly260265270AsnSerSerSerProHisLeuLeuAspGlnLeuLysAlaGlnAsnGln275280285GluLeuArgAsnLysIleAsnGluLeuGluLeuArgLeuGlnGlyHis290295300GluLysGluMetLysGlyGlnValAsnLysPheGlnGluLeuGlnLeu305310315320GlnLeuGluLysAlaLysValGluLeuIleGluLysGluLysValLeu325330335AsnLysCysArgAspGluLeuValArgThrThrAlaGlnTyrAspGln340345350AlaSerThrLysTyrThrAlaLeuGluGlnLysLeuLysLysLeuThr355360365GluAspLeuSerCysGlnArgGlnAsnAlaGluSerAlaArgCysSer370375380LeuGluGlnLysIleLysGluLysGluLysGluPheGlnGluGluLeu385390395400SerArgGlnGlnArgSerPheGlnThrLeuAspGlnGluCysIleGln405410415MetLysAlaArgLeuThrGlnGluLeuGlnGlnAlaLysAsnMetHis420425430AsnValLeuGlnAlaGluLeuAspLysLeuThrSerValLysGlnGln435440445LeuGluAsnAsnLeuGluGluPheLysGlnLysLeuCysArgAlaGlu450455460GlnAlaPheGlnAlaSerGlnIleLysGluAsnGluLeuArgArgSer465470475480MetGluGluMetLysLysGluAsnAsnLeuLeuLysSerHisSerGlu485490495GlnLysAlaArgGluValCysHisLeuGluAlaGluLeuLysAsnIle500505510LysGlnCysLeuAsnGlnSerGlnAsnPheAlaGluGluMetLysAla515520525LysAsnThrSerGlnGluThrMetLeuArgAspLeuGlnGluLysIle530535540AsnGlnGlnGluAsnSerLeuThrLeuGluLysLeuLysLeuAlaVal545550555560AlaAspLeuGluLysGlnArgAspCysSerGlnAspLeuLeuLysLys565570575ArgGluHisHisIleGluGlnLeuAsnAspLysLeuSerLysThrGlu580585590LysGluSerLysAlaLeuLeuSerAlaLeuGluLeuLysLysLysGlu595600605TyrGluGluLeuLysGluGluLysThrLeuPheSerCysTrpLysSer610615620GluAsnGluLysLeuLeuThrGlnMetGluSerGluLysGluAsnLeu625630635640GlnSerLysIleAsnHisLeuGluThrCysLeuLysThrGlnGlnIle645650655LysSerHisGluTyrAsnGluArgValArgThrLeuGluMetAspArg660665670GluAsnLeuSerValGluIleArgAsnLeuHisAsnValLeuAspSer675680685LysSerValGluValGluThrGlnLysLeuAlaTyrMetGluLeuGln690695700GlnLysAlaGluPheSerAspGlnLysHisGlnLysGluIleGluAsn705710715720MetCysLeuLysThrSerGlnLeuThrGlyGlnValGluAspLeuGlu725730735HisLysLeuGlnLeuLeuSerAsnGluIleMetAspLysAspArgCys740745750TyrGlnAspLeuHisAlaGluTyrGluSerLeuArgAspLeuLeuLys755760765SerLysAspAlaSerLeuValThrAsnGluAspHisGlnArgSerLeu770775780LeuAlaPheAspGlnGlnProAlaMetHisHisSerPheAlaAsnIle785790795800IleGlyGluGlnGlySerMetProSerGluArgSerGluCysArgLeu805810815GluAlaAspGlnSerProLysAsnSerAlaIleLeuGlnAsnArgVal820825830AspSerLeuGluPheSerLeuGluSerGlnLysGlnMetAsnSerAsp835840845LeuGlnLysGlnCysGluGluLeuValGlnIleLysGlyGluIleGlu850855860GluAsnLeuMetLysAlaGluGlnMetHisGlnSerPheValAlaGlu865870875880ThrSerGlnArgIleSerLysLeuGlnGluAspThrSerAlaHisGln885890895AsnValValAlaGluThrLeuSerAlaLeuGluAsnLysGluLysGlu900905910LeuGlnLeuLeuAsnAspLysValGluThrGluGlnAlaGluIleGln915920925GluLeuLysLysSerAsnHisLeuLeuGluAspSerLeuLysGluLeu930935940GlnLeuLeuSerGluThrLeuSerLeuGluLysLysGluMetSerSer945950955960IleIleSerLeuAsnLysArgGluIleGluGluLeuThrGlnGluAsn965970975GlyThrLeuLysGluIleAsnAlaSerLeuAsnGlnGluLysMetAsn980985990LeuIleGlnLysSerGluSerPheAlaAsnTyrIleAspGluArgGlu99510001005LysSerIleSerGluLeuSerAspGlnTyrLysGlnGluLysLeuIle101010151020LeuLeuGlnArgCysGluGluThrGlyAsnAlaTyrGluAspLeuSer1025103010351040GlnLysTyrLysAlaAlaGlnGluLysAsnSerLysLeuGluCysLeu104510501055LeuAsnGluCysThrSerLeuCysGluAsnArgLysAsnGluLeuGlu106010651070GlnLeuLysGluAlaPheAlaLysGluHisGlnGluPheLeuThrLys107510801085LeuAlaPheAlaGluGluArgAsnGlnAsnLeuMetLeuGluLeuGlu109010951100ThrValGlnGlnAlaLeuArgSerGluMetThrAspAsnGlnAsnAsn1105111011151120SerLysSerGluAlaGlyGlyLeuLysGlnGluIleMetThrLeuLys112511301135GluGluGlnAsnLysMetGlnLysGluValAsnAspLeuLeuGlnGlu114011451150AsnGluGlnLeuMetLysValMetLysThrLysHisGluCysGlnAsn115511601165LeuGluSerGluProIleArgAsnSerValLysGluArgGluSerGlu117011751180ArgAsnGlnCysAsnPheLysProGlnMetAspLeuGluValLysGlu1185119011951200IleSerLeuAspSerTyrAsnAlaGlnLeuValGlnLeuGluAlaMet120512101215LeuArgAsnLysGluLeuLysLeuGlnGluSerGluLysGluLysGlu122012251230CysLeuGlnHisGluLeuGlnThrIleArgGlyAspLeuGluThrSer123512401245AsnLeuGlnAspMetGlnSerGlnGluIleSerGlyLeuLysAspCys125012551260GluIleAspAlaGluGluLysTyrIleSerGlyProHisGluLeuSer1265127012751280ThrSerGlnAsnAspAsnAlaHisLeuGlnCysSerLeuGlnThrThr128512901295MetAsnLysLeuAsnGluLeuGluLysIleCysGluIleLeuGlnAla130013051310GluLysTyrGluLeuValThrGluLeuAsnAspSerArgSerGluCys131513201325IleThrAlaThrArgLysMetAlaGluGluValGlyLysLeuLeuAsn133013351340GluValLysIleLeuAsnAspAspSerGlyLeuLeuHisGlyGluLeu1345135013551360ValGluAspIleProGlyGlyGluPheGlyGluGlnProAsnGluGln136513701375HisProValSerLeuAlaProLeuAspGluSerAsnSerTyrGluHis138013851390LeuThrLeuSerAspLysGluValGlnMetHisPheAlaGluLeuGln139514001405GluLysPheLeuSerLeuGlnSerGluHisLysIleLeuHisAspGln141014151420HisCysGlnMetSerSerLysMetSerGluLeuGlnThrTyrValAsp1425143014351440SerLeuLysAlaGluAsnLeuValLeuSerThrAsnLeuArgAsnPhe144514501455GlnGlyAspLeuValLysGluMetGlnLeuGlyLeuGluGluGlyLeu146014651470ValProSerLeuSerSerSerCysValProAspSerSerSerLeuSer147514801485SerLeuGlyAspSerSerPheTyrArgAlaLeuLeuGluGlnThrGly149014951500AspMetSerLeuLeuSerAsnLeuGluGlyAlaValSerAlaAsnGln1505151015151520CysSerValAspGluValPheCysSerSerLeuGlnThrTyrValAsp152515301535SerLeuLysAlaGluAsnLeuValLeuSerThrAsnLeuArgAsnPhe154015451550GlnGlyAspLeuValLysGluMetGlnLeuGlyLeuGluGluGlyLeu155515601565ValProSerLeuSerSerSerCysValProAspSerSerSerLeuSer157015751580SerLeuGlyAspSerSerPheTyrArgAlaLeuLeuGluGlnThrGly1585159015951600AspMetSerLeuLeuSerAsnLeuGluGlyValValSerAlaAsnGln160516101615CysSerValAspGluValPheCysSerSerLeuGlnGluGluAsnLeu162016251630ThrArgLysGluThrProSerAlaProAlaLysGlyValGluGluLeu163516401645GluSerLeuCysGluValTyrArgGlnSerLeuGluLysLeuGluGlu165016551660LysMetGluSerGlnGlyIleMetLysAsnLysGluIleGlnGluLeu1665167016751680GluGlnLeuLeuSerSerGluArgGlnGluLeuAspCysLeuArgLys168516901695GlnTyrLeuSerGluAsnGluGlnTrpGlnGlnLysLeuThrSerVal170017051710ThrLeuGluMetGluSerLysLeuAlaAlaGluLysLysGlnThrGlu171517201725GlnLeuSerLeuGluLeuGluValAlaArgLeuGlnLeuGlnGlyLeu173017351740AspLeuSerSerArgSerLeuLeuGlyIleAspThrGluAspAlaIle1745175017551760GlnGlyArgAsnGluSerCysAspIleSerLysGluHisThrSerGlu176517701775ThrThrGluArgThrProLysHisAspValHisGlnIleCysAspLys178017851790AspAlaGlnGlnAspLeuAsnLeuAspIleGluLysIleThrGluThr179518001805GlyAlaValLysProThrGlyGluCysSerGlyGluGlnSerProAsp181018151820ThrAsnTyrGluProProGlyGluAspLysThrGlnGlySerSerGlu1825183018351840CysIleSerGluLeuSerPheSerGlyProAsnAlaLeuValProMet184518501855AspPheLeuGlyAsnGlnGluAspIleHisAsnLeuGlnLeuArgVal186018651870LysGluThrSerAsnGluAsnLeuArgLeuLeuHisValIleGluAsp187518801885ArgAspArgLysValGluSerLeuLeuAsnGluMetLysGluLeuAsp189018951900SerLysLeuHisLeuGlnGluValGlnLeuMetThrLysIleGluAla1905191019151920CysIleGluLeuGluLysIleValGlyGluLeuLysLysGluAsnSer192519301935AspLeuSerGluLysLeuGluTyrPheSerCysAspHisGlnGluLeu194019451950LeuGlnArgValGluThrSerGluGlyLeuAsnSerAspLeuGluMet195519601965HisAlaAspLysSerSerArgGluAspIleGlyAspAsnValAlaLys197019751980ValAsnAspSerTrpLysGluArgPheLeuAspValGluAsnGluLeu1985199019952000SerArgIleArgSerGluLysAlaSerIleGluHisGluAlaLeuTyr200520102015LeuGluAlaAspLeuGluValValGlnThrGluLysLeuCysLeuGlu202020252030LysAspAsnGluAsnLysGlnLysValIleValCysLeuGluGluGlu203520402045LeuSerValValThrSerGluArgAsnGlnLeuArgGlyGluLeuAsp205020552060ThrMetSerLysLysThrThrAlaLeuAspGlnLeuSerGluLysMet2065207020752080LysGluLysThrGlnGluLeuGluSerHisGlnSerGluCysLeuHis208520902095CysIleGlnValAlaGluAlaGluValLysGluLysThrGluLeuLeu210021052110GlnThrLeuSerSerAspValSerGluLeuLeuLysAspLysThrHis211521202125LeuGlnGluLysLeuGlnSerLeuGluLysAspSerGlnAlaLeuSer213021352140LeuThrLysCysGluLeuGluAsnGlnIleAlaGlnLeuAsnLysGlu2145215021552160LysGluLeuLeuValLysGluSerGluSerLeuGlnAlaArgLeuSer216521702175GluSerAspTyrGluLysLeuAsnValSerLysAlaLeuGluAlaAla218021852190LeuValGluLysGlyGluPheAlaLeuArgLeuSerSerThrGlnGlu219522002205GluValHisGlnLeuArgArgGlyIleGluLysLeuArgValArgIle221022152220GluAlaAspGluLysLysGlnLeuHisIleAlaGluLysLeuLysGlu2225223022352240ArgGluArgGluAsnAspSerLeuLysAspLysValGluAsnLeuGlu224522502255ArgGluLeuGlnMetSerGluGluAsnGlnGluLeuValIleLeuAsp226022652270AlaGluAsnSerLysAlaGluValGluThrLeuLysThrGlnIleGlu227522802285GluMetAlaArgSerLeuLysIlePheGluLeuAspLeuValThrLeu229022952300ArgSerGluLysGluAsnLeuThrLysGlnIleGlnGluLysGlnGly2305231023152320GlnLeuSerGluLeuAspLysLeuLeuSerSerPheLysSerLeuLeu232523302335GluGluLysGluGlnAlaGluIleGlnIleLysGluGluSerLysThr234023452350AlaValGluMetLeuGlnAsnGlnLeuLysGluLeuAsnGluAlaVal235523602365AlaAlaLeuCysGlyAspGlnGluIleMetLysAlaThrGluGlnSer237023752380LeuAspProProIleGluGluGluHisGlnLeuArgAsnSerIleGlu2385239023952400LysLeuArgAlaArgLeuGluAlaAspGluLysLysGlnLeuCysVal240524102415LeuGlnGlnLeuLysGluSerGluHisHisAlaAspLeuLeuLysGly242024252430ArgValGluAsnLeuGluArgGluLeuGluIleAlaArgThrAsnGln243524402445GluHisAlaAlaLeuGluAlaGluAsnSerLysGlyGluValGluThr245024552460LeuLysAlaLysIleGluGlyMetThrGlnSerLeuArgGlyLeuGlu2465247024752480LeuAspValValThrIleArgSerGluLysGluAsnLeuThrAsnGlu248524902495LeuGlnLysGluGlnGluArgIleSerGluLeuGluIleIleAsnSer250025052510SerPheGluAsnIleLeuGlnGluLysGluGlnGluLysValGlnMet251525202525LysGluLysSerSerThrAlaMetGluMetLeuGlnThrGlnLeuLys253025352540GluLeuAsnGluArgValAlaAlaLeuHisAsnAspGlnGluAlaCys2545255025552560LysAlaLysGluGlnAsnLeuSerSerGlnValGluCysLeuGluLeu256525702575GluLysAlaGlnLeuLeuGlnGlyLeuAspGluAlaLysAsnAsnTyr258025852590IleValLeuGlnSerSerValLysGlyLeuIleGlnGluValGluAsp259526002605GlyLysGlnLysLeuGluLysLysAspGluGluIleSerArgLeuLys261026152620AsnGlnIleGlnAspGlnGluGlnLeuValSerLysLeuSerGlnVal2625263026352640GluGlyGluHisGlnLeuTrpLysGluGlnAsnLeuGluLeuArgAsn264526502655LeuThrValGluLeuGluGlnLysIleGlnValLeuGlnSerLysAsn266026652670AlaSerLeuGlnAspThrLeuGluValLeuGlnSerSerTyrLysAsn267526802685LeuGluAsnGluLeuGluLeuThrLysMetAspLysMetSerPheVal269026952700GluLysValAsnLysMetThrAlaLysGluThrGluLeuGlnArgGlu2705271027152720MetHisGluMetAlaGlnLysThrAlaGluLeuGlnGluGluLeuSer272527302735GlyGluLysAsnArgLeuAlaGlyGluLeuGlnLeuLeuLeuGluGlu274027452750IleLysSerSerLysAspGlnLeuLysGluLeuThrLeuGluAsnSer275527602765GluLeuLysLysSerLeuAspCysMetHisLysAspGlnValGluLys277027752780GluGlyLysValArgGluGluIleAlaGluTyrGlnLeuArgLeuHis2785279027952800GluAlaGluLysLysHisGlnAlaLeuLeuLeuAspThrAsnLysGln280528102815TyrGluValGluIleGlnThrTyrArgGluLysLeuThrSerLysGlu282028252830GluCysLeuSerSerGlnLysLeuGluIleAspLeuLeuLysSerSer283528402845LysGluGluLeuAsnAsnSerLeuLysAlaThrThrGlnIleLeuGlu285028552860GluLeuLysLysThrLysMetAspAsnLeuLysTyrValAsnGlnLeu2865287028752880LysLysGluAsnGluArgAlaGlnGlyLysMetLysLeuLeuIleLys288528902895SerCysLysGlnLeuGluGluGluLysGluIleLeuGlnLysGluLeu290029052910SerGlnLeuGlnAlaAlaGlnGluLysGlnLysThrGlyThrValMet291529202925AspThrLysValAspGluLeuThrThrGluIleLysGluLeuLysGlu293029352940ThrLeuGluGluLysThrLysGluAlaAspGluTyrLeuAspLysTyr2945295029552960CysSerLeuLeuIleSerHisGluLysLeuGluLysAlaLysGluMet296529702975LeuGluThrGlnValAlaHisLeuCysSerGlnGlnSerLysGlnAsp298029852990SerArgGlySerProLeuLeuGlyProValValProGlyProSerPro299530003005IleProSerValThrGluLysArgLeuSerSerGlyGlnAsnLysAla301030153020SerGlyLysArgGlnArgSerSerGlyIleTrpGluAsnGlyArgGly3025303030353040ProThrProAlaThrProGluSerPheSerLysLysSerLysLysAla304530503055ValMetSerGlyIleHisProAlaGluAspThrGluGlyThrGluPhe306030653070GluProGluGlyLeuProGluValValLysLysGlyPheAlaAspIle307530803085ProThrGlyLysThrSerProTyrIleLeuArgArgThrThrMetAla309030953100ThrArgThrSerProArgLeuAlaAlaGlnLysLeuAlaLeuSerPro3105311031153120LeuSerLeuGlyLysGluAsnLeuAlaGluSerSerLysProThrAla312531303135GlyGlySerArgSerGlnLysValLysValAlaGlnArgSerProVal314031453150AspSerGlyThrIleLeuArgGluProThrThrLysSerValProVal315531603165AsnAsnLeuProGluArgSerProThrAspSerProArgGluGlyLeu317031753180ArgValLysArgGlyArgLeuValProAlaProLysLeuAspTrpSer3185319031953200GlnLeuAlaValArgThrValArgSerSerGluAlaLeuCysValSer320532103215AspProTrpGluValGlnSerLeuIleAspArgLeuCysLeuGlnAsp322032253230PheSerLeuValArgAlaCysPheIleSerGluGluLysThrIlePro323532403245(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 10136 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA to mRNA(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A) ORGANISM: HUMAN(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:GGAGAAGCGGGCGAATTGGGCACCGGTGGCGGCTGCGGGCAGTTTGAATTAGACTCTGGG60CTCCAGCCCGCCGAAGCCGCGCCAGAACTGTACTCTCCGAGAGGTCGTTTTCCCGTCCCC120GAGAGCAAGTTTATTTACAAATGTTGGAGTAATAAAGAAGGCAGAACAAAATGAGCTGGG180CTTTGGAAGAATGGAAAGAAGGGCTGCCTACAAGAACTCTTCAGAAAATTCAAGAGCTTG240AAGGACAGCTTGACAAACTGAAGAAGGAAAAGCAGCAAAGGCAGTTTCAGCTTGACAGTC300TCGAGGCTGCGCCGCAGAAGCAAACACAGAAGGTTGAAAATGAAAAAACCGAGGGTACAA360ACCTGAAAAGGGAGAATCAAAGATTGATGGAAATATGTGAAAGTCTGGAGAAAACTAAGC420AGAAGATTTCTCATGAACTTCAAGTCAAGGAGTCACAAGTGAATTTCCAGGAAGGACAAC480TGAATTCAGGCAAAAAACAAATAGAAAAACTGGAACAGGAACTTAAAAGGTGTAAATCTG540AGCTTGAAAGAAGCCAACAAGCTGCGCAGTCTGCAGATGTCTCTCTGAATCCATGCAATA600CACCACAAAAAATTTTTACAACTCCACTAACACCAAGTCAATATTATAGTGGTTCCAAGT660ATGAAGATCTAAAAGAAAAATATAATAAAGAGGTTGAAGAACGAAAAAGATTAGAGGCAG720AGGTTAAAGCCTTGCAGGCTAAAAAAGCAAGCCAGACTCTTCCACAAGCCACCATGAATC780ACCGCGACATTGCCCGGCATCAGGCTTCATCATCTGTGTTCTCATGGCAGCAAGAGAAGA840CCCCAAGTCATCTTTCATCTAATTCTCAAAGAACTCCAATTAGGAGAGATTTCTCTGCAT900CTTACTTTTCTGGGGAACTAGAGGTGACTCCAAGTCGATCAACTTTGCAAATAGGGAAAA960GAGATGCTAATAGCAGTTTCTTTGGCAATTCTAGCAGTCCTCATCTTTTGGATCAATTAA1020AAGCGCAGAATCAAGAGCTAAGAAACAAGATTAATGAGTTGGAACTACGCCTGCAAGGAC1080ATGAAAAAGAAATGAAAGGCCAAGTGAATAAGTTTCAAGAACTCCAACTCCAACTGGAGA1140AAGCAAAAGTGGAATTAATTGAAAAAGAGAAAGTTTTGAACAAATGTAGGGATGAACTAG1200TGAGAACAACAGCACAATACGACCAGGCGTCAACCAAGTATACTGCATTGGAACAAAAAC1260TGAAAAAATTGACGGAAGATTTGAGTTGTCAGCGACAAAATGCAGAAAGTGCCAGATGTT1320CTCTGGAACAGAAAATTAAGGAAAAAGAAAAGGAGTTTCAAGAGGAGCTCTCCCGTCAAC1380AGCGTTCTTTCCAAACACTGGACCAGGAGTGCATCCAGATGAAGGCCAGACTCACCCAGG1440AGTTACAGCAAGCCAAGAATATGCACAACGTCCTGCAGGCTGAACTGGATAAACTCACAT1500CAGTAAAGCAACAGCTAGAAAACAATTTGGAAGAGTTTAAGCAAAAGTTGTGCAGAGCTG1560AACAGGCGTTCCAGGCGAGTCAGATCAAGGAGAATGAGCTGAGGAGAAGCATGGAGGAAA1620TGAAGAAGGAAAACAACCTCCTTAAGAGTCACTCTGAGCAAAAGGCCAGAGAAGTCTGCC1680ACCTGGAGGCAGAACTCAAGAACATCAAACAGTGTTTAAATCAGAGCCAGAATTTTGCAG1740AAGAAATGAAAGCGAAGAATACCTCTCAGGAAACCATGTTAAGAGATCTTCAAGAAAAAA1800TAAATCAGCAAGAAAACTCCTTGACTTTAGAAAAACTGAAGCTTGCTGTGGCTGATCTGG1860AAAAGCAGCGAGATTGTTCTCAAGACCTTTTGAAGAAAAGAGAACATCACATTGAACAAC1920TTAATGATAAGTTAAGCAAGACAGAGAAAGAGTCCAAAGCCTTGCTGAGTGCTTTAGAGT1980TAAAAAAGAAAGAATATGAAGAATTGAAAGAAGAGAAAACTCTGTTTTCTTGTTGGAAAA2040GTGAAAACGAAAAACTTTTAACTCAGATGGAATCAGAAAAGGAAAACTTGCAGAGTAAAA2100TTAATCACTTGGAAACTTGTCTGAAGACACAGCAAATAAAAAGTCATGAATACAACGAGA2160GAGTAAGAACGCTGGAGATGGACAGAGAAAACCTAAGTGTCGAGATCAGAAACCTTCACA2220ACGTGTTAGACAGTAAGTCAGTGGAGGTAGAGACCCAGAAACTAGCTTATATGGAGCTAC2280AGCAGAAAGCTGAGTTCTCAGATCAGAAACATCAGAAGGAAATAGAAAATATGTGTTTGA2340AGACTTCTCAGCTTACTGGGCAAGTTGAAGATCTAGAACACAAGCTTCAGTTACTGTCAA2400ATGAAATAATGGACAAAGACCGGTGTTACCAAGACTTGCATGCCGAATATGAGAGCCTCA2460GGGATCTGCTAAAATCCAAAGATGCTTCTCTGGTGACAAATGAAGATCATCAGAGAAGTC2520TTTTGGCTTTTGATCAGCAGCCTGCCATGCATCATTCCTTTGCAAATATAATTGGAGAAC2580AAGGAAGCATGCCTTCAGAGAGGAGTGAATGTCGTTTAGAAGCAGACCAAAGTCCGAAAA2640ATTCTGCCATCCTACAAAATAGAGTTGATTCACTTGAATTTTCATTAGAGTCTCAAAAAC2700AGATGAACTCAGACCTGCAAAAGCAGTGTGAAGAGTTGGTGCAAATCAAAGGAGAAATAG2760AAGAAAATCTCATGAAAGCAGAACAGATGCATCAAAGTTTTGTGGCTGAAACAAGTCAGC2820GCATTAGTAAGTTACAGGAAGACACTTCTGCTCACCAGAATGTTGTTGCTGAAACCTTAA2880GTGCCCTTGAGAACAAGGAAAAAGAGCTGCAACTTTTAAATGATAAGGTAGAAACTGAGC2940AGGCAGAGATTCAAGAATTAAAAAAGAGCAACCATCTACTTGAAGACTCTCTAAAGGAGC3000TACAACTTTTATCCGAAACCCTAAGCTTGGAGAAGAAAGAAATGAGTTCCATCATTTCTT3060TAAATAAAAGGGAAATTGAAGAGCTGACCCAAGAGAATGGGACTCTTAAGGAAATTAATG3120CATCCTTAAATCAAGAGAAGATGAACTTAATCCAGAAAAGTGAGAGTTTTGCAAACTATA3180TAGATGAAAGGGAGAAAAGCATTTCAGAGTTATCTGATCAGTACAAGCAAGAAAAACTTA3240TTTTACTACAAAGATGTGAAGAAACCGGAAATGCATATGAGGATCTTAGTCAAAAATACA3300AAGCAGCACAGGAAAAGAATTCTAAATTAGAATGCTTGCTAAATGAATGCACTAGTCTTT3360GTGAAAATAGGAAAAATGAGTTGGAACAGCTAAAGGAAGCATTTGCAAAGGAACACCAAG3420AATTCTTAACAAAATTAGCATTTGCTGAAGAAAGAAATCAGAATCTGATGCTAGAGTTGG3480AGACAGTGCAGCAAGCTCTGAGATCTGAGATGACAGATAACCAAAACAATTCTAAGAGCG3540AGGCTGGTGGTTTAAAGCAAGAAATCATGACTTTAAAGGAAGAACAAAACAAAATGCAAA3600AGGAAGTTAATGACTTATTACAAGAGAATGAACAGCTGATGAAGGTAATGAAGACTAAAC3660ATGAATGTCAAAATCTAGAATCAGAACCAATTAGGAACTCTGTGAAAGAAAGAGAGAGTG3720AGAGAAATCAATGTAATTTTAAACCTCAGATGGATCTTGAAGTTAAAGAAATTTCTCTAG3780ATAGTTATAATGCGCAGTTGGTGCAATTAGAAGCTATGCTAAGAAATAAGGAATTAAAAC3840TTCAGGAAAGTGAGAAGGAGAAGGAGTGCCTGCAGCATGAATTACAGACAATTAGAGGAG3900ATCTTGAAACCAGCAATTTGCAAGACATGCAGTCACAAGAAATTAGTGGCCTTAAAGACT3960GTGAAATAGATGCGGAAGAAAAGTATATTTCAGGGCCTCATGAGTTGTCAACAAGTCAAA4020ACGACAATGCACACCTTCAGTGCTCTCTGCAAACAACAATGAACAAGCTGAATGAGCTAG4080AGAAAATATGTGAAATACTGCAGGCTGAAAAGTATGAACTCGTAACTGAGCTGAATGATT4140CAAGGTCAGAATGTATCACAGCAACTAGGAAAATGGCAGAAGAGGTAGGGAAACTACTAA4200ATGAAGTTAAAATATTAAATGATGACAGTGGTCTTCTCCATGGTGAGTTAGTGGAAGACA4260TACCAGGAGGTGAATTTGGTGAACAACCAAATGAACAGCACCCTGTGTCTTTGGCTCCAT4320TGGACGAGAGTAATTCCTACGAGCACTTGACATTGTCAGACAAAGAAGTTCAAATGCACT4380TTGCCGAATTGCAAGAGAAATTCTTATCTTTACAAAGTGAACACAAAATTTTACATGATC4440AGCACTGTCAGATGAGCTCTAAAATGTCAGAGCTGCAGACCTATGTTGACTCATTAAAGG4500CCGAAAATTTGGTCTTGTCAACGAATCTGAGAAACTTTCAAGGTGACTTGGTGAAGGAGA4560TGCAGCTGGGCTTGGAGGAGGGGCTCGTTCCATCCCTGTCATCCTCTTGTGTGCCTGACA4620GCTCTAGTCTTAGCAGTTTGGGAGACTCCTCCTTTTACAGAGCTCTTTTAGAACAGACAG4680GAGATATGTCTCTTTTGAGTAATTTAGAAGGGGCTGTTTCAGCAAACCAGTGCAGTGTAG4740ATGAAGTATTTTGCAGCAGTCTGCAGACCTATGTTGACTCATTAAAGGCCGAAAATTTGG4800TCTTGTCAACGAATCTGAGAAACTTTCAAGGTGACTTGGTGAAGGAGATGCAGCTGGGCT4860TGGAGGAGGGGCTCGTTCCATCCCTGTCATCCTCTTGTGTGCCTGACAGCTCTAGTCTTA4920GCAGTTTGGGAGACTCCTCCTTTTACAGAGCTCTTTTAGAACAGACAGGAGATATGTCTC4980TTTTGAGTAATTTAGAAGGGGTTGTTTCAGCAAACCAGTGCAGTGTAGATGAAGTATTTT5040GCAGCAGTCTGCAGGAGGAGAATCTGACCAGGAAAGAAACCCCTTCGGCCCCAGCGAAGG5100GTGTTGAAGAGCTTGAGTCCCTCTGTGAGGTGTACCGGCAGTCCCTCGAGAAGCTAGAAG5160AGAAAATGGAAAGTCAAGGGATTATGAAAAATAAGGAAATTCAAGAGCTCGAGCAGTTAT5220TAAGTTCTGAAAGGCAAGAGCTTGACTGCCTTAGGAAGCAGTATTTGTCAGAAAATGAAC5280AGTGGCAACAGAAGCTGACAAGCGTGACTCTGGAGATGGAGTCCAAGTTGGCGGCAGAAA5340AGAAACAGACGGAACAACTGTCACTTGAGCTGGAAGTAGCACGACTCCAGCTACAAGGTC5400TGGACTTAAGTTCTCGGTCTTTGCTTGGCATCGACACAGAAGATGCTATTCAAGGCCGAA5460ATGAGAGCTGTGACATATCAAAAGAACATACTTCAGAAACTACAGAAAGAACACCAAAGC5520ATGATGTTCATCAGATTTGTGATAAAGATGCTCAGCAGGACCTCAATCTAGACATTGAGA5580AAATAACTGAGACTGGTGCAGTGAAACCCACAGGAGAGTGCTCTGGGGAACAGTCCCCAG5640ATACCAATTATGAGCCTCCAGGGGAAGATAAAACCCAGGGCTCTTCAGAATGCATTTCTG5700AATTGTCATTTTCTGGTCCTAATGCTTTGGTACCTATGGATTTCCTGGGGAATCAGGAAG5760ATATCCATAATCTTCAACTGCGGGTAAAAGAGACATCAAATGAGAATTTGAGATTACTTC5820ATGTGATAGAGGACCGTGACAGAAAAGTTGAAAGTTTGCTAAATGAAATGAAAGAATTAG5880ACTCAAAACTCCATTTACAGGAGGTACAACTAATGACCAAAATTGAAGCATGCATAGAAT5940TGGAAAAAATAGTTGGGGAACTTAAGAAAGAAAACTCAGATTTAAGTGAAAAATTGGAAT6000ATTTTTCTTGTGATCACCAGGAGTTACTCCAGAGAGTAGAAACTTCTGAAGGCCTCAATT6060CTGATTTAGAAATGCATGCAGATAAATCATCACGTGAAGATATTGGAGATAATGTGGCCA6120AGGTGAATGACAGCTGGAAGGAGAGATTTCTTGATGTGGAAAATGAGCTGAGTAGGATCA6180GATCGGAGAAAGCTAGCATTGAGCATGAAGCCCTCTACCTGGAGGCTGACTTAGAGGTAG6240TTCAAACAGAGAAGCTATGTTTAGAAAAAGACAATGAAAATAAGCAGAAGGTTATTGTCT6300GCCTTGAAGAAGAACTCTCAGTGGTCACAAGTGAGAGAAACCAGCTTCGTGGAGAATTAG6360ATACTATGTCAAAAAAAACCACGGCACTGGATCAGTTGTCTGAAAAAATGAAGGAGAAAA6420CACAAGAGCTTGAGTCTCATCAAAGTGAGTGTCTCCATTGCATTCAGGTGGCAGAGGCAG6480AGGTGAAGGAAAAGACGGAACTCCTTCAGACTTTGTCCTCTGATGTGAGTGAGCTGTTAA6540AAGACAAAACTCATCTCCAGGAAAAGCTGCAGAGTTTGGAAAAGGACTCACAGGCACTGT6600CTTTGACAAAATGTGAGCTGGAAAACCAAATTGCACAACTGAATAAAGAGAAAGAATTGC6660TTGTCAAGGAATCTGAAAGCCTGCAGGCCAGACTGAGTGAATCAGATTATGAAAAGCTGA6720ATGTCTCCAAGGCCTTGGAGGCCGCACTGGTGGAGAAAGGTGAGTTCGCATTGAGGCTGA6780GCTCAACACAGGAGGAAGTGCATCAGCTGAGAAGAGGCATCGAGAAACTGAGAGTTCGCA6840TTGAGGCCGATGAAAAGAAGCAGCTGCACATCGCAGAGAAACTGAAAGAACGCGAGCGGG6900AGAATGATTCACTTAAGGATAAAGTTGAGAACCTTGAAAGGGAATTGCAGATGTCAGAAG6960AAAACCAGGAGCTAGTGATTCTTGATGCCGAGAATTCCAAAGCAGAAGTAGAGACTCTAA7020AAACACAAATAGAAGAGATGGCCAGAAGCCTGAAGATTTTTGAATTAGACCTTGTCACGT7080TAAGGTCTGAAAAAGAAAATCTGACAAAACAAATACAAGAAAAACAAGGTCAGTTGTCAG7140AACTAGACAAGTTACTCTCTTCATTTAAAAGTCTGTTAGAAGAAAAGGAGCAAGCAGAGA7200TACAGATCAAAGAAGAATCTAAAACTGCAGTGGAGATGCTTCAGAATCAGTTAAAGGAGC7260TAAATGAGGCAGTAGCAGCCTTGTGTGGTGACCAAGAAATTATGAAGGCCACAGAACAGA7320GTCTAGACCCACCAATAGAGGAAGAGCATCAGCTGAGAAATAGCATTGAAAAGCTGAGAG7380CCCGCCTAGAAGCTGATGAAAAGAAGCAGCTCTGTGTCTTACAACAACTGAAGGAAAGTG7440AGCATCATGCAGATTTACTTAAGGGTAGAGTGGAGAACCTTGAAAGAGAGCTAGAGATAG7500CCAGGACAAACCAAGAGCATGCAGCTCTTGAGGCAGAGAATTCCAAAGGAGAGGTAGAGA7560CCCTAAAAGCAAAAATAGAAGGGATGACCCAAAGTCTGAGAGGTCTGGAATTAGATGTTG7620TTACTATAAGGTCAGAAAAAGAAAATCTGACAAATGAATTACAAAAAGAGCAAGAGCGAA7680TATCTGAATTAGAAATAATAAATTCATCATTTGAAAATATTTTGCAAGAAAAAGAGCAAG7740AGAAAGTACAGATGAAAGAAAAATCAAGCACTGCCATGGAGATGCTTCAAACACAATTAA7800AAGAGCTCAATGAGAGAGTGGCAGCCCTGCATAATGACCAAGAAGCCTGTAAGGCCAAAG7860AGCAGAATCTTAGTAGTCAAGTAGAGTGTCTTGAACTTGAGAAGGCTCAGTTGCTACAAG7920GCCTTGATGAGGCCAAAAATAATTATATTGTTTTGCAATCTTCAGTGAAAGGCCTCATTC7980AAGAAGTAGAAGATGGCAAGCAGAAACTGGAGAAGAAGGATGAAGAAATCAGTAGACTGA8040AAAATCAAATTCAAGACCAAGAGCAGCTTGTCTCTAAACTGTCCCAGGTGGAAGGAGAGC8100ACCAACTTTGGAAGGAGCAAAACTTAGAACTGAGAAATCTGACGGTGGAATTGGAGCAGA8160AGATCCAAGTGCTACAATCCAAAAATGCCTCTTTGCAGGACACATTAGAAGTGCTGCAGA8220GTTCTTACAAGAATCTAGAGAATGAGCTTGAATTGACAAAAATGGACAAAATGTCCTTTG8280TTGAAAAAGTAAACAAAATGACTGCAAAGGAAACTGAGCTGCAGAGGGAAATGCATGAGA8340TGGCACAGAAAACAGCAGAGCTGCAAGAAGAACTCAGTGGAGAGAAAAATAGGCTAGCTG8400GAGAGTTGCAGTTACTGTTGGAAGAAATAAAGAGCAGCAAAGATCAATTGAAGGAGCTCA8460CACTAGAAAATAGTGAATTGAAGAAGAGCCTAGATTGCATGCACAAAGACCAGGTGGAAA8520AGGAAGGGAAAGTGAGAGAGGAAATAGCTGAATATCAGCTACGGCTTCATGAAGCTGAAA8580AGAAACACCAGGCTTTGCTTTTGGACACAAACAAACAGTATGAAGTAGAAATCCAGACAT8640ACCGAGAGAAATTGACTTCTAAAGAAGAATGTCTCAGTTCACAGAAGCTGGAGATAGACC8700TTTTAAAGTCTAGTAAAGAAGAGCTCAATAATTCATTGAAAGCTACTACTCAGATTTTGG8760AAGAATTGAAGAAAACCAAGATGGACAATCTAAAATATGTAAATCAGTTGAAGAAGGAAA8820ATGAACGTGCCCAGGGGAAAATGAAGTTGTTGATCAAATCCTGTAAACAGCTGGAAGAGG8880AAAAGGAGATACTGCAGAAAGAACTCTCTCAACTTCAAGCTGCACAGGAGAAGCAGAAAA8940CAGGTACTGTTATGGATACCAAGGTCGATGAATTAACAACTGAGATCAAAGAACTGAAAG9000AAACTCTTGAAGAAAAAACCAAGGAGGCAGATGAATACTTGGATAAGTACTGTTCCTTGC9060TTATAAGCCATGAAAAGTTAGAGAAAGCTAAAGAGATGTTAGAGACACAAGTGGCCCATC9120TGTGTTCACAGCAATCTAAACAAGATTCCCGAGGGTCTCCTTTGCTAGGTCCAGTTGTTC9180CAGGACCATCTCCAATCCCTTCTGTTACTGAAAAGAGGTTATCATCTGGCCAAAATAAAG9240CTTCAGGCAAGAGGCAAAGATCCAGTGGAATATGGGAGAATGGTAGAGGACCAACACCTG9300CTACCCCAGAGAGCTTTTCTAAAAAAAGCAAGAAAGCAGTCATGAGTGGTATTCACCCTG9360CAGAAGACACGGAAGGTACTGAGTTTGAGCCAGAGGGACTTCCAGAAGTTGTAAAGAAAG9420GGTTTGCTGACATCCCGACAGGAAAGACTAGCCCATATATCCTGCGAAGAACAACCATGG9480CAACTCGGACCAGCCCCCGCCTGGCTGCACAGAAGTTAGCGCTATCCCCACTGAGTCTCG9540GCAAAGAAAATCTTGCAGAGTCCTCCAAACCAACAGCTGGTGGCAGCAGATCACAAAAGG9600TCAAAGTTGCTCAGCGGAGCCCAGTAGATTCAGGCACCATCCTCCGAGAACCCACCACGA9660AATCCGTCCCAGTCAATAATCTTCCTGAGAGAAGTCCGACTGACAGCCCCAGAGAGGGCC9720TGAGGGTCAAGCGAGGCCGACTTGTCCCAGCCCCAAAGCTGGACTGGAGTCAACTGGCAG9780TGAGAACTGTAAGGTCCAGCGAAGCACTTTGTGTGTCAGACCCTTGGGAGGTGCAGTCAT9840TGATAGATAGGCTGTGCCTACAGGACTTCTCTTTAGTCAGGGCATGCTTTATTAGTGAGG9900AGAAAACAATTCCTTAGAAGTCTTAAATATATTGTACTCTTTAGATCTCCCATGTGTAGG9960TATTGAAAAAGTTTGGAAGCACTGATCACCTGTTAGCATTGCCATTCCTCTACTGCAATG10020TAAATAGTATAAAGCTATGTATATAAAGCTTTTTGGTAATATGTTACAATTAAAATGACA10080AGCACTATATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA10136(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:CTTTTGCTTTCTCCAGTTGG20(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:TTGACGCCTGGTCGTATTG19__________________________________________________________________________
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1994012521A1 *Nov 19, 1993Jun 9, 1994Univ TexasCellular genes encoding retinoblastoma-associated proteins
Non-Patent Citations
Reference
1 *Dalmau et al., 1990, Ann. Neurol., 27:544 552.
2Dalmau et al., 1990, Ann. Neurol., 27:544-552.
3 *Gerdes et al., 1983, Int. J. Cancer, 31:13 20.
4Gerdes et al., 1983, Int. J. Cancer, 31:13-20.
5 *Hall et al., 1990, J. Pathol., 162:285 294.
6Hall et al., 1990, J. Pathol., 162:285-294.
7 *Hitchock, C. L., 1991, Am. J. Clin. Pathol., 96:444 445.
8Hitchock, C. L., 1991, Am. J. Clin. Pathol., 96:444-445.
9 *Kreipe et al., 1993, Am. J. Pathol., 142:651 657.
10Kreipe et al., 1993, Am. J. Pathol., 142:651-657.
11 *Leonardi et al., 1992, J. Clin. Pathol., (London) 45:416 419.
12Leonardi et al., 1992, J. Clin. Pathol., (London) 45:416-419.
13 *Mathews et al., 1984, Nature, 309:374 376.
14Mathews et al., 1984, Nature, 309:374-376.
15 *Miyachi et al., 1978, J. Immunol., 121:2228 2234.
16Miyachi et al., 1978, J. Immunol., 121:2228-2234.
17 *Peterson et al., 1992, Neurology, 42:1931 1937.
18Peterson et al., 1992, Neurology, 42:1931-1937.
19 *Peterson, C. L., 1994, Cell, 79:389 392.
20Peterson, C. L., 1994, Cell, 79:389-392.
21 *Rattner et al., 1991, J. Immunol., 146:2341 2344.
22Rattner et al., 1991, J. Immunol., 146:2341-2344.
23 *Rattner et al., 1993, Cell Motility and the Cytoskeleton, 26:214 226.
24Rattner et al., 1993, Cell Motility and the Cytoskeleton, 26:214-226.
25 *Rattner, J. B., Principles of Clinical Flow Cytometry; in Clinical Flow Cytometry Principles and Applications , Bauer, Duque and Sharkey eds. (1993), pp. 28 40.
26Rattner, J. B., Principles of Clinical Flow Cytometry; in Clinical Flow Cytometry Principles and Applications, Bauer, Duque and Sharkey eds. (1993), pp. 28-40.
27 *Sampson et al., 1992, J. Pathol. 168:179 185.
28Sampson et al., 1992, J. Pathol. 168:179-185.
29 *Zhu et al. (1995) Mol. Cell. Biol. 15: 5017 5029.
30Zhu et al. (1995) Mol. Cell. Biol. 15: 5017-5029.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6527689 *Jul 15, 1999Mar 4, 2003Incyte Genomics, Inc.Maternally transcribed protein
US7498149 *Feb 27, 2004Mar 3, 2009Japan Science And Technology AgencyProteins having effects of controlling cell migration and cell death
US7662572Aug 25, 2006Feb 16, 2010Platypus Technologies, Llc.for use in assay for detection of viruses, cells, bacteria, lipid-membrane containing organisms, proteins, nucleic acids, carbohydrates and other biomolecules; portable
US7666661 *Aug 26, 2002Feb 23, 2010Platypus Technologies, LlcSubstrates, devices, and methods for quantitative liquid crystal assays
US7829670Feb 26, 2008Nov 9, 2010Japan Science And Technology AgencyFilamin A interacting protein 1 for use in directed destruction of actin binding protein filamin-1; treating neurodegenerative disorders
US7842499Aug 7, 2007Nov 30, 2010Platypus Technologies, LlcDispension apparatus for depositing cell mixture into channels of multiwell plates
US8178355Sep 15, 2009May 15, 2012Platypus Technologies, Llc.Detection of vapor phase compounds by changes in physical properties of a liquid crystal
US8268614Nov 10, 2004Sep 18, 2012Platypus Technologies, LlcMethod for assaying cell movement
US8512974Sep 14, 2012Aug 20, 2013Platypus Technologies, LlcMethod for assaying cell movement
WO2001033229A1 *Nov 1, 2000May 10, 2001Driel Roeland VanMethod for the detection of mammalian carcinomas
Classifications
U.S. Classification536/23.5
International ClassificationC07K14/47
Cooperative ClassificationC07K14/47
European ClassificationC07K14/47
Legal Events
DateCodeEventDescription
Jul 28, 2008FPAYFee payment
Year of fee payment: 12
Apr 17, 2008ASAssignment
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF
Free format text: CONFIRMATORY LICENSE;ASSIGNOR:FOX CHASE CANCER CENTER;REEL/FRAME:020819/0457
Effective date: 19960919
Jul 14, 2004FPAYFee payment
Year of fee payment: 8
Jul 19, 2000FPAYFee payment
Year of fee payment: 4
Apr 6, 1995ASAssignment
Owner name: FOX CHASE CANCER CENTER
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YEN, TIMOTHY J.;REEL/FRAME:007421/0239
Effective date: 19950222